{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:57:25Z","timestamp":1758776245508,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Parathyroid hormone (PTH) excess is associated with hypertension while elevated PTH has been observed in primary aldosteronism (PA). This study aimed to determine the proportion of patients with hyperparathyroidism who met Endocrine Society criteria for PA screening, and to assess current screening practices.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Multi-centre retrospective cohort study including patients attending outpatient endocrine clinics at three tertiary health services in Victoria, Australia between 2015\u20132019. Patients were included if they had an elevated PTH level and excluded if they had a secondary cause of hyperparathyroidism or a prior diagnosis of PA. Demographic, clinical and biochemical data were extracted from electronic medical records.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 275 patients with hyperparathyroidism, hypertension was present in 51.6%; including 62.4% of patients with hypercalcaemia and 35.5% of those with normocalcaemia. Overall,15.6% (43\/275) had a guideline indication for PA screening, including 21.8% (36\/165) of those with hypercalcaemia and 6.4% (7\/110) of those with normocalcaemia. Of those with hypertension, 30% (43\/142) had a guideline indication for PA screening. The most common indication for screening was hypertension and hypokalaemia (16\/43). Despite this, only 9.3% (4\/43) were screened, with one confirmed PA diagnosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Hypertension is common in patients with hyperparathyroidism. A third of patients with hyperparathyroidism and hypertension had a guideline indication for PA screening, however screening remains substantially under-utilised. A prospective study is needed to evaluate the prevalence and impact of PA in patients with hyperparathyroidism.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-025-04323-7","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T05:29:17Z","timestamp":1751520557000},"page":"339-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indications for primary aldosteronism screening in people with hypertension and hyperparathyroidism: a multi-centre cohort study"],"prefix":"10.1007","volume":"90","author":[{"given":"A","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Sztal-Mazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Milat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gilfillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"6","key":"4323_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"D.A. Calhoun, M.K. Nishizaka, M.A. Zaman, R.B. Thakkar, P. Weissmann, Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6), 892\u2013896 (2002).","journal-title":"Hypertension"},{"issue":"14","key":"4323_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo, P. Mulatero, Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. Journal Am. Coll. Cardiol. 69(14), 1811\u20131820 (2017).","journal-title":"Journal Am. Coll. Cardiol."},{"issue":"8","key":"4323_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5694\/mja2.51438","volume":"216","author":"R Libianto","year":"2022","unstructured":"R. Libianto, G.M. Russell, M. Stowasser, S.M. Gwini, P. Nuttall, J. Shen, J. Yang, Detecting primary aldosteronism in Australian primary care: a prospective study. Medical J. Aust. 216(8), 408\u2013412 (2022).","journal-title":"Medical J. Aust."},{"issue":"1","key":"4323_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita, P. Mulatero, Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. lancet Diabetes Endocrinol. 6(1), 41\u201350 (2018).","journal-title":"lancet Diabetes Endocrinol."},{"issue":"5","key":"4323_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1530\/EJE-15-0450","volume":"173","author":"G Hanslik","year":"2015","unstructured":"G. Hanslik, H. Wallaschofski, A. Dietz, A. Riester, M. Reincke, B. Allolio, A. Hannemann, Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn\u2019s Registry. Eur J. Endocrinol. 173(5), 665\u2013675 (2015).","journal-title":"Eur J. Endocrinol."},{"issue":"6","key":"4323_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamasurg.2021.0254","volume":"156","author":"YY Liu","year":"2021","unstructured":"Y.Y. Liu, J. King, G.A. Kline, R.S. Padwal, J.L. Pasieka, G. Chen, A.A. Leung, Outcomes of a specialized clinic on rates of investigation and treatment of primary aldosteronism. JAMA Surg. 156(6), 541\u2013549 (2021).","journal-title":"JAMA Surg."},{"issue":"2","key":"4323_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/HJH.0b013e32834f0451","volume":"30","author":"C Maniero","year":"2012","unstructured":"C. Maniero, A. Fassina, T.M. Seccia, A. Toniato, M. Iacobone, M. Plebani, G.P. Rossi, Mild hyperparathyroidism: a novel surgically correctable feature of primary aldosteronism. Journal Hypertension 30(2), 390\u2013395 (2012).","journal-title":"Journal Hypertension"},{"issue":"04","key":"4323_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/a-1027-6472","volume":"128","author":"E Asbach","year":"2020","unstructured":"E. Asbach, M. Bekeran, A. K\u00f6nig, K. Lang, G. Hanslik, M. Treitl, M. Reincke, Primary and secondary hyperparathyroidism in patients with primary aldosteronism\u2013findings from the German Conn\u2019s registry. Experimental Clin. Endocrinol. Diabetes 128(04), 246\u2013254 (2020).","journal-title":"Experimental Clin. Endocrinol. Diabetes"},{"key":"4323_CR9","doi-asserted-by":"publisher","first-page":"836529","DOI":"10.1155\/2014\/836529","volume":"2014","author":"L Petramala","year":"2014","unstructured":"L. Petramala, L. Zinnamosca, A. Settevendemmie, C. Marinelli, M. Nardi, A. Concistr\u00e8, C. Letizia, Bone and mineral metabolism in patients with primary aldosteronism. International J. Endocrinol. 2014, 836529 (2014).","journal-title":"International J. Endocrinol."},{"issue":"12","key":"4323_CR10","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1210\/en.2011-1515","volume":"152","author":"AJ Koh","year":"2011","unstructured":"A.J. Koh, C.M. Novince, X. Li, T. Wang, R.S. Taichman, L.K. McCauley, An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. Endocrinology 152(12), 4525\u20134536 (2011).","journal-title":"Endocrinology"},{"issue":"1","key":"4323_CR11","doi-asserted-by":"publisher","first-page":"H286","DOI":"10.1152\/ajpheart.00535.2005","volume":"290","author":"A Vidal","year":"2006","unstructured":"A. Vidal, Y. Sun, S.K. Bhattacharya, R.A. Ahokas, I.C. Gerling, K.T. Weber, Calcium paradox of aldosteronism and the role of the parathyroid glands. American J. Physiol.-Heart Circulatory Physiol. 290(1), H286\u2013H294 (2006).","journal-title":"American J. Physiol.-Heart Circulatory Physiol."},{"issue":"8","key":"4323_CR12","first-page":"e10391","volume":"4","author":"G Zavatta","year":"2020","unstructured":"G. Zavatta, B.L. Clarke, Normocalcemic hyperparathyroidism: a heterogeneous disorder often misdiagnosed?. JBMR 4(8), e10391 (2020).","journal-title":"JBMR"},{"key":"4323_CR13","doi-asserted-by":"publisher","unstructured":"F. Milat, S.K. Ramchand, M. Herath, J. Gundara, S. Harper, S. Farrell, C.M. Girgis, R. Clifton-Bligh, H.G. Schneider, S.M.C. De Sousa, A.J. Gill, J. Serpell, K. Taubman, J. Christie, R.W. Carroll, J.A. Miller, M. Grossmann, Primary hyperparathyroidism in adults-(Part I) assessment and medical management: Position statement of the endocrine society of Australia, the Australian & New Zealand endocrine surgeons, and the Australian & New Zealand bone and mineral society. Clinical Endocrinology. (2021). https:\/\/doi.org\/10.1111\/cen.14659","DOI":"10.1111\/cen.14659"},{"issue":"10","key":"4323_CR14","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jbmr.1660","volume":"27","author":"AS Salcuni","year":"2012","unstructured":"A.S. Salcuni, S. Palmieri, V. Carnevale, V. Morelli, C. Battista, V. Guarnieri, I. Chiodini, Bone involvement in aldosteronism. Journal Bone Miner. Res. 27(10), 2217\u20132222 (2012).","journal-title":"Journal Bone Miner. Res."},{"issue":"5","key":"4323_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-9343(99)80239-3","volume":"99","author":"J Rastad","year":"1995","unstructured":"J. Rastad, G. Akerstr\u00f6m, S. Ljunghall, Mortality of untreated primary hyperparathyroidism-a nontraditional indication for parathyroid surgery?. American J. Med. 99(5), 577\u2013578 (1995).","journal-title":"American J. Med."},{"issue":"6","key":"4323_CR16","doi-asserted-by":"publisher","first-page":"R297","DOI":"10.1530\/EJE-17-0485","volume":"177","author":"J Pepe","year":"2017","unstructured":"J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. European J. Endocrinol. 177(6), R297\u2013R308 (2017).","journal-title":"European J. Endocrinol."},{"issue":"1","key":"4323_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/cen.12206","volume":"79","author":"N Yu","year":"2013","unstructured":"N. Yu, G.P. Leese, P.T. Donnan, What predicts adverse outcomes in untreated primary hyperparathyroidism? the parathyroid epidemiology and audit research study (PEARS). Clinical Endocrinol. 79(1), 27\u201334 (2013).","journal-title":"Clinical Endocrinol."},{"issue":"1","key":"4323_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jocd.2012.12.001","volume":"16","author":"NE Cusano","year":"2013","unstructured":"N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. Journal Clin. Densitom. 16(1), 33\u201339 (2013).","journal-title":"Journal Clin. Densitom."},{"issue":"5","key":"4323_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata, W.F. Young Jr, The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. Journal Clin. Endocrinol. Metab. 101(5), 1889\u20131916 (2016).","journal-title":"Journal Clin. Endocrinol. Metab."},{"key":"4323_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","volume":"79","author":"GL Hundemer","year":"2022","unstructured":"G.L. Hundemer, H. Imsirovic, A. Vaidya, N. Yozamp, Screening rates of primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. J Hypertension 79, 178\u2013186 (2022).","journal-title":"J Hypertension"},{"key":"4323_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.31128\/AJGP-05-18-4587","volume":"47","author":"YY Lim","year":"2018","unstructured":"Y.Y. Lim, J. Shen, P.J. Fuller, L. Yang, Current patterns of primary aldosteronism diagnosis: delayed and complicated. Australian J. Gen. Pract. 47, 712\u2013718 (2018).","journal-title":"Australian J. Gen. Pract."},{"key":"4323_CR22","unstructured":"Australian Bureau of Statistics. (2022). National Health Survey. ABS, https:\/\/www.abs.gov.au\/statistics\/health\/health-conditions-and-risks\/national-health-survey\/latest-release. Accessed 12 May 2022."},{"issue":"9","key":"4323_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.4158\/EP.14.9.1133","volume":"14","author":"J Muthukrishnan","year":"2008","unstructured":"J. Muthukrishnan, K.V. Hari Kumar, R. Jha, S. Jha, K.D. Modi, Distal renal tubular acidosis due to primary hyperparathyroidism. Endocrine Pract. 14(9), 1133\u20131136 (2008). https:\/\/doi.org\/10.4158\/EP.14.9.1133.","journal-title":"Endocrine Pract."},{"issue":"1","key":"4323_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvs092","volume":"94","author":"A Tomaschitz","year":"2012","unstructured":"A. Tomaschitz, E. Ritz, B. Pieske, A. Fahrleitner-Pammer, K. Kienreich, J.H. Horina, C. Drechsler, W. M\u00e4rz, M. Ofner, T.R. Pieber, S. Pilz, Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovascular Res. 94(1), 10\u201319 (2012). https:\/\/doi.org\/10.1093\/cvr\/cvs092.","journal-title":"Cardiovascular Res."},{"issue":"3","key":"4323_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MED.0000000000000062","volume":"21","author":"JM Brown","year":"2014","unstructured":"J.M. Brown, A. Vaidya, Interactions between adrenal-regulatory and calcium-regulatory hormones in human health. Current Opin. Endocrinol., Diabetes Obes. 21(3), 193\u2013201 (2014). https:\/\/doi.org\/10.1097\/MED.0000000000000062.","journal-title":"Current Opin. Endocrinol., Diabetes Obes."},{"key":"4323_CR26","first-page":"45","volume":"132","author":"I Sotornik","year":"1993","unstructured":"I. Sotornik, J. Stribrna, J. Hronova, V. Kocandrle, V. Janata, P. Taborsky et al., Changes in plasma renin and aldosterone after parathyroidectomy in patients with hyperparathyroidism. Casopis L\u00e9kar\u016f Cesk\u00fdch 132, 45\u201349 (1993).","journal-title":"Casopis L\u00e9kar\u016f Cesk\u00fdch"},{"key":"4323_CR27","first-page":"1035","volume":"146","author":"L Brunaud","year":"2009","unstructured":"L. Brunaud, A. Germain, R. Zarnegar, M. Rancier, S. Alrasheedi, C. Caillard et al., Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism. Surger 146, 1035\u20131041 (2009).","journal-title":"Surger"},{"issue":"9","key":"4323_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/jhh.2014.125","volume":"29","author":"A Vaidya","year":"2015","unstructured":"A. Vaidya, J.M. Brown, J.S. Williams, The renin-angiotensin-aldosterone system and calcium-regulatory hormones. Journal Hum. Hypertension 29(9), 515\u2013521 (2015). https:\/\/doi.org\/10.1038\/jhh.2014.125.","journal-title":"Journal Hum. Hypertension"},{"key":"4323_CR29","doi-asserted-by":"publisher","unstructured":"A. Ooi, H. Khan, M. Akram, P.J. Fuller, F. Milat, J. Yang, R. Libianto, Changes in parathyroidism hormone across the spectrum of renin-independent aldosteronism. J. Clin. Endocrinol. Metab. dgaf151 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgaf151.","DOI":"10.1210\/clinem\/dgaf151"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:27Z","timestamp":1758772827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4323"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04323-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}